RecruitingPhase 4NCT05309460

Labetalol or Nifedipine for Control of Postpartum Hypertension: A Randomized Controlled Trial


Sponsor

Nebraska Methodist Health System

Enrollment

600 participants

Start Date

Jun 20, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

Randomized trial comparing risk of hospital readmission and hypertensive complications between patients managed on Labetalol compared to Nifedipine.


Eligibility

Sex: FEMALEMin Age: 19 Years

Plain Language Summary

Simplified for easier understanding

This study compares two blood pressure medications — labetalol and nifedipine — to find out which is safer and more effective for controlling high blood pressure after childbirth (postpartum hypertension). High blood pressure after delivery is a serious but common complication. **You may be eligible if...** - You delivered a baby (vaginally or by C-section) at 24 weeks of pregnancy or later - You have high blood pressure after delivery (systolic ≥140 mmHg or diastolic ≥90 mmHg on two separate readings) - You speak English or Spanish **You may NOT be eligible if...** - You have moderate or severe persistent asthma, coronary artery disease, heart failure, a heart block, or fluid in the lungs (pulmonary edema) - You have a medical reason you cannot take either nifedipine or labetalol - Your heart rate is below 60 or above 110 beats per minute - Your primary language is not English or Spanish Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGLabetalol Oral Tablet

See Labetalol arm.

DRUGNIFEdipine ER

See Nifedipine arm.


Locations(1)

Nebraska Methodist Women's Hospital

Omaha, Nebraska, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05309460


Related Trials